Eugen Schlegel

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Daniel K. Burns, Robert Alexander, Kathleen A. Welsh‐Bohmer et al. · The Lancet Neurology · 2021 · 117 citations

Medicine, Pharmacology, Pharmacotherapy +14

Incidence and mitigation of gastrointestinal events in patients with relapsing–remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)

Ralf Gold, Eugen Schlegel, Birte Elias-Hamp et al. · Therapeutic Advances in Neurological Disorders · 2018 · 24 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +13

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

María Trojano, Helmut Butzkueven, Ludwig Kappos et al. · Multiple Sclerosis and Related Disorders · 2018 · 19 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients

Thomas Müller, Eugen Schlegel, Stephanie Zingler et al. · Cells · 2022 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16